Filament Health To Supply Psilocybin For Proposed Belgian Compassionate Use Program
By Elizabeth Urbanek, Executive Editor
Filament Health has signed a supply and licensing agreement with Belgian nonprofit Epsylon ASBL to provide PEX010, its standardized botanical psilocybin drug candidate, for a proposed compassionate use program for treatment-resistant depression. The program must receive regulatory approval before patients can access the treatment outside a clinical trial.
Rhelion Life Sciences, Filament's parent company, announced the agreement October 16. Epsylon is the program applicant and will lead its conduct under the direction of Dr. Daniel Souery. Filament will supply PEX010 and provide regulatory support. The program is also supported by Psychedelic Society Belgium, a nonprofit organization that advocates for regulated access to psychedelic-assisted therapy.
Rhelion describes the proposal as a potential first for Belgium, where the company says psilocybin is currently available only through clinical trials. The Belgian Federal Agency for Medicines and Health Products must approve the compassionate use program. Relevant ethics approval and any necessary import and export authorizations must also be obtained before the program can proceed.
Why Clinical Supply Should Care
Compassionate use programs introduce supply requirements that differ from those of conventional clinical trials. Access depends not only on the availability of an investigational medicine but also on authorization for the specific program, product and intended use. In Belgium, the proposed program is tied to PEX010 and must receive regulatory approval before it can provide treatment outside a clinical trial.
The agreement establishes a cross-border supply relationship between a product supplier and a Belgian program applicant. Filament is responsible for supplying the medicine, while Epsylon is responsible for conducting the program. Filament's regulatory support may help the applicant address product-related requirements, but the announcement does not detail the parties' responsibilities for shipment timing, packaging, labeling, distribution or inventory management.
PEX010 is a botanical psilocybin drug candidate that Filament says is manufactured under GMP and available in standardized 1 mg, 5 mg and 25 mg doses. The company says a 0.5 mg dose is planned for future availability. The announcement does not specify which strengths the Belgian program would use, how much product it would require or how supply would be scheduled if approval is granted.
These details matter because product availability alone does not establish readiness to supply a new access program. Regulatory authorization, product release, cross-border permits and coordination between the supplier and program operator must align before supply can support patient treatment. Rhelion's announcement identifies program approval, relevant ethics approval and necessary import and export authorizations as dependencies.
The announcement does not indicate that Filament or Epsylon has encountered a supply problem. Instead, it illustrates how a new access pathway can create coordination requirements across product supply, regulatory approval and program operations before treatment can begin.
The Supply Question
How should suppliers and program applicants coordinate product readiness, regulatory authorization and cross-border supply when establishing a compassionate use program for an investigational medicine?
Related Clinical Supply Leader Editorials:
- How Clinical Supply Teams Can Prevent Cross-Border Shipping Delays
- Regulatory Readiness in Clinical Supply: Building a Culture of Compliance, Part 1
About The Author:
Elizabeth Urbanek is the Executive Editor for Clinical Supply Leader, where she works with clinical trial supply and logistics professionals across pharma and biotech to bring real-world perspectives, operational challenges, trends, scientific insights and regulatory strategy to the field.
Before joining life sciences media, Elizabeth spent more than 15 years in broadcast, digital and live-event storytelling, helping highly technical teams communicate complex ideas with clarity and impact. She brings that same approach to clinical supply, creating editorial space for experts to share what is happening across clinical trial operations.
Elizabeth is passionate about connecting people and ideas, identifying emerging themes and showcasing work that can move the clinical supply field forward.